We are live on ! Find out more
IBO

Impact BioMedical
IBO

21 hedge funds and large institutions have $358K invested in Impact BioMedical in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

17% more capital invested

Capital invested by funds: $305K → $358K (+$53.2K)

11% more funds holding

Funds holding: 19 → 21 (+2)

0.51% more ownership

Funds ownership: 3.9% → 4.42% (+0.51%)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

Holders
21
Holders Change
+2
Holders Change %
+10.53%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$44.4K
2
TSS
Two Sigma Securities
New York
+$17.9K
3
MAC
Mason & Associates (California)
California
+$6.31K
4
Morgan Stanley
Morgan Stanley
New York
+$5.84K
5
Two Sigma Investments
Two Sigma Investments
New York
+$5.55K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$12.4K
2
SG
StoneX Group
New York
-$6.99K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$6.22K
4
HF
HRT Financial
New York
-$6K
5
Citigroup
Citigroup
New York
-$3.4K

IBO Hedge Fund Activity: Q3 2025 in Review

21 of the 7,643 institutional investors tracked by Wall St. Rank reported a position in Impact BioMedical (IBO) for Q3 2025, worth a combined $358K — up 17% from $305K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new IBO positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 5 trimmed.

The largest buyer was Vanguard Group, adding an estimated $44.4K. The largest seller was UBS Group, cutting an estimated $12.4K.

  • 21 institutional investors held Impact BioMedical (IBO) as of Q3 2025, up from 19 in Q2 2025.
  • Funds reported $358K of Impact BioMedical stock for Q3 2025, up 17% quarter-over-quarter.
  • 4 funds opened new Impact BioMedical positions in Q3 2025 and 2 closed out, a net change of +2 holders.
  • The largest Impact BioMedical buyer in Q3 2025 was Vanguard Group, an estimated $44.4K added.
  • The largest Impact BioMedical seller in Q3 2025 was UBS Group, an estimated $12.4K sold.

Based on aggregated 13F filings for Q3 2025.